Meeting
2023 ASCO Annual Meeting
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.
Authors
Anne C. Chiang
Yale University School of Medicine, New Haven, CT
Anne C. Chiang , Hossein Asghari , Kerryan Ashley , Scott N. Gettinger , Sarah B. Goldberg , Roy S. Herbst , Frederick Hugh Wilson , Benjamin Robert Newton , Michael Keith Cohenuram , Kert D. Sabbath , Ashita D. Talsania , Armand Vincent Russo , Eric Schultz , Stan Skrzypczak , Carl Kingsford , Kurt A. Schalper
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Small Cell Lung Cancer
Clinical Trial Registration Number
NCT03670056
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 8597)
DOI
10.1200/JCO.2023.41.16_suppl.8597
Abstract #
8597
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Genomic predictors of benefit from checkpoint inhibition in neuroendocrine carcinoma.
First Author: Patrick Walsh McGarrah
Poster
2021 Gastrointestinal Cancers Symposium
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
First Author: Jeffrey Sum Lung Wong
Poster
2020 ASCO Virtual Scientific Program
Nivolumab (Nivo) and ipilimumab (Ipi) in combination with radiotherapy (RT) in high-risk patients (pts) with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).
First Author: Jennifer Maria Johnson